Oruka Therapeutics

Clinical-stage biotech developing extended half-life antibodies for chronic skin diseases, targeting IL-23p19 (ORKA-001) and IL-17A/F (ORKA-002). Goal is high rates of complete disease clearance with dosing as infrequent as once or twice a year in plaque psoriasis.